Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cryptosporidium phosphatidylinositol 4-kinase (PI4K or CpPI(4)K) is a lipid kinase enzyme found in the protozoan parasite *Cryptosporidium*, which causes cryptosporidiosis. PI4K catalyzes the phosphorylation of phosphatidylinositol (PI) to generate phosphatidylinositol 4-phosphate (PI4P), a key lipid signaling molecule involved in various cellular processes. It is essential for parasite growth and survival within host cells, making it a validated drug target. Inhibitors targeting this kinase have shown potent anti-parasitic effects. CpPI(4)Ks differ structurally from their human counterparts enough to allow selective inhibition.
Competitive inhibition at the ATP-binding site
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cryptosporidium phosphatidylinositol 4-kinase (CpPI(4)K).